J T Olin

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Provisional diagnostic criteria for depression of Alzheimer disease
    Jason T Olin
    Adult and Geriatric Treatment and Preventive Interventions Research Branch, National Institute of Mental Health, Bethesda, MD 20892 9635, USA
    Am J Geriatr Psychiatry 10:125-8. 2002
  2. ncbi request reprint A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease
    J T Olin
    Geriatric Psychopharmacology Program, Adult and Geriatric Treatment and Preventive Interventions Research Branch, National Institute of Mental Health, 6001 Executive Blvd, Rm 7160 MSC 9635, Bethesda, MD 20892 9635, USA
    Am J Geriatr Psychiatry 9:400-5. 2001
  3. ncbi request reprint Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background
    Jason T Olin
    Adult and Geriatric Treatment and Preventive Interventions Research Branch, National Institute of Mental Health, Bethesda, MD 20892 9635, USA
    Am J Geriatr Psychiatry 10:129-41. 2002
  4. ncbi request reprint Career development and training in geriatric mental health: report of an NIMH workshop
    Jason T Olin
    National Institute of Mental Health, 6001 Executive Boulevard, Room 7160, MSC 9635, Bethesda, MD 20892 9635, USA
    Am J Geriatr Psychiatry 11:275-9. 2003
  5. ncbi request reprint Increasing ethnic minority participation in Alzheimer disease research
    Jason T Olin
    Division of Service and Intervention Research, National Institute of Mental Health, Bethesda, Maryland 20892 9635, USA
    Alzheimer Dis Assoc Disord 16:S82-5. 2002
  6. ncbi request reprint Depression and Bipolar Support Alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in late life
    Dennis S Charney
    National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
    Arch Gen Psychiatry 60:664-72. 2003
  7. ncbi request reprint Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future
    Warachal E Faison
    Alzheimer s Research and Clinical Programs, Neurosciences Department, Medical University of South Carolina, Charleston, South Carolina 29406, USA
    Int Psychogeriatr 19:539-58. 2007
  8. ncbi request reprint Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment
    Howard H Feldman
    Division of Neurology, University of British Columbia, Vancouver, BC, Canada
    Alzheimer Dis Assoc Disord 20:263-8. 2006
  9. ncbi request reprint Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis
    Frederick A Schmitt
    Department of Neurology, University of Kentucky Medical Center, Sanders Brown Center on Aging, Lexington, KY 40536, USA
    Alzheimer Dis Assoc Disord 20:255-62. 2006
  10. ncbi request reprint Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial
    Elaine R Peskind
    Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine and Veterans Affairs Northwest Network Mental Illness Research, Education, and Clinical Center, Seattle, WA 98108, USA
    Am J Geriatr Psychiatry 14:704-15. 2006

Detail Information

Publications13

  1. ncbi request reprint Provisional diagnostic criteria for depression of Alzheimer disease
    Jason T Olin
    Adult and Geriatric Treatment and Preventive Interventions Research Branch, National Institute of Mental Health, Bethesda, MD 20892 9635, USA
    Am J Geriatr Psychiatry 10:125-8. 2002
    ....
  2. ncbi request reprint A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease
    J T Olin
    Geriatric Psychopharmacology Program, Adult and Geriatric Treatment and Preventive Interventions Research Branch, National Institute of Mental Health, 6001 Executive Blvd, Rm 7160 MSC 9635, Bethesda, MD 20892 9635, USA
    Am J Geriatr Psychiatry 9:400-5. 2001
    ..The effect on global ratings was similar to those found in an earlier report in nursing home residents...
  3. ncbi request reprint Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background
    Jason T Olin
    Adult and Geriatric Treatment and Preventive Interventions Research Branch, National Institute of Mental Health, Bethesda, MD 20892 9635, USA
    Am J Geriatr Psychiatry 10:129-41. 2002
    ..Further research is needed to better define core symptoms, clinical course, and efficacy of treatments...
  4. ncbi request reprint Career development and training in geriatric mental health: report of an NIMH workshop
    Jason T Olin
    National Institute of Mental Health, 6001 Executive Boulevard, Room 7160, MSC 9635, Bethesda, MD 20892 9635, USA
    Am J Geriatr Psychiatry 11:275-9. 2003
    ..Federal, public, and private mechanisms need to be better leveraged to grow late-life mental-illness research infrastructure and meet increasing demand and scientific opportunities...
  5. ncbi request reprint Increasing ethnic minority participation in Alzheimer disease research
    Jason T Olin
    Division of Service and Intervention Research, National Institute of Mental Health, Bethesda, Maryland 20892 9635, USA
    Alzheimer Dis Assoc Disord 16:S82-5. 2002
    ..Fundamentally, researchers should consider that these strategies apply to all potential research participants, and not simply to traditionally underserved racial/ethnic populations...
  6. ncbi request reprint Depression and Bipolar Support Alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in late life
    Dennis S Charney
    National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
    Arch Gen Psychiatry 60:664-72. 2003
    ..To review progress made during the past decade in late-life mood disorders and to identify areas of unmet need in health care delivery and research...
  7. ncbi request reprint Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future
    Warachal E Faison
    Alzheimer s Research and Clinical Programs, Neurosciences Department, Medical University of South Carolina, Charleston, South Carolina 29406, USA
    Int Psychogeriatr 19:539-58. 2007
    ..for AD to answer two questions: (1) what are the challenges to diagnose and treat AD across different ethnic groups, and (2) are there differences in response to pharmacologic interventions for AD across these different ethnic groups?..
  8. ncbi request reprint Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment
    Howard H Feldman
    Division of Neurology, University of British Columbia, Vancouver, BC, Canada
    Alzheimer Dis Assoc Disord 20:263-8. 2006
    ..These post hoc analyses in moderate-to-severe AD patients receiving stable donepezil treatment suggest that memantine may impact overall functional levels, and some of the cognitive processing underlying ADL performance...
  9. ncbi request reprint Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis
    Frederick A Schmitt
    Department of Neurology, University of Kentucky Medical Center, Sanders Brown Center on Aging, Lexington, KY 40536, USA
    Alzheimer Dis Assoc Disord 20:255-62. 2006
    ....
  10. ncbi request reprint Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial
    Elaine R Peskind
    Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine and Veterans Affairs Northwest Network Mental Illness Research, Education, and Clinical Center, Seattle, WA 98108, USA
    Am J Geriatr Psychiatry 14:704-15. 2006
    ..The objective of this study was to compare the efficacy and safety of the moderate-affinity, uncompetitive N-methyl-d-aspartate receptor antagonist, memantine, versus placebo in patients with mild to moderate Alzheimer disease (AD)...
  11. ncbi request reprint A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil
    Christopher H van Dyck
    Department of Psychiatry, Yale University, New Haven, Connecticut 06510, USA
    Am J Geriatr Psychiatry 14:428-37. 2006
    ..The objective of this study was to examine the clinical utility of memantine for moderate-to-severe Alzheimer disease (AD) using responder analyses...
  12. ncbi request reprint Proxy and surrogate consent in geriatric neuropsychiatric research: update and recommendations
    Scott Y H Kim
    Department of Psychiatry and the Program in Clinical Ethics, University of Rochester Medical Center, Rochester, NY, USA
    Am J Psychiatry 161:797-806. 2004
    ..The authors provide an updated discussion, critique, and recommendations regarding the need for clear legal and regulatory policy on this issue...
  13. ncbi request reprint Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial
    Anton P Porsteinsson
    Alzheimer s Disease Care, Research and Education Program, University of Rochester, School of Medicine and Dentistry, Rochester, NY 14620, USA
    Curr Alzheimer Res 5:83-9. 2008
    ..To evaluate the efficacy and safety of memantine in patients with mild to moderate Alzheimer's disease (AD) receiving cholinesterase inhibitor (ChEI) treatment...